Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke

• Published in: Experimental and therapeutic medicine Vol. 11; no. 5; pp. 2015 - 2020
• Main Authors: XUE, LI-XIA, ZHANG, TING, ZHAO, YU-WU, GENG, ZHI, CHEN, JING-JIONG, CHEN, HAO
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.05.2016; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: acute ischemic stroke; Analysis; Blood; Blood-brain barrier; Care and treatment; Cerebrolysin; Clinical trials; DL-3-n-butylphthalide; Ischemia; Laboratories; NMR; Nuclear magnetic resonance; Oral drugs; Patient outcomes; Patients; Software; Standard deviation; Stroke; Urine; Values; Variance analysis; China; acute ischemic stroke; Cerebrolysin; DL-3-n-butylphthalide
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2016.3139

Cerebrolysin and DL-3-n-butylphthalide (NBP) have each shown neuroprotective efficacy in preclinical models of acute ischemic stroke (AIS) and passed clinical trials as therapeutic drugs for AIS. The present study was a clinical trial to assess and compare the efficacy and safety of NBP and Cerebrolysin in the reduction of neurological and behavioral disability following AIS. A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS. In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) scores were used to evaluate the efficacy of the treatment in the patients with AIS at 11 and 21 days after the initiation of therapy. Adverse events were also analyzed among the three groups. After 10 days of treatment with NBP or Cerebrolysin, the NIHSS and BI scores at day 21 showed statistical differences compared with those in the placebo group (P<0.05). The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05). A statistically significant difference in the improvement of 21-day NIHSS scores was observed between the two treatment groups (P<0.05). No significant difference was found among the three groups with regard to the rate of adverse events. Favorable outcomes and good safety were observed in the patients with moderate AIS treated with NBP or Cerebrolysin. The results indicate that NBP may be more effective than Cerebrolysin in improving short-term outcomes following AIS. This trial is registered at ClinicalTrials.gov with clinical trial identifier number NCT02149875.